Drug intelligence / Profile preview

culevibart

Development stage: Unknown
Lead developer: Reyoung Biopharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intramuscular

Overview

Yingmule (culevibart; RB0026) is a long-acting recombinant human IgG1κ monoclonal antibody developed by Reyoung Biopharmaceutical for the prevention of respiratory syncytial virus (RSV)-related lower respiratory tract infections in newborns and infants. It targets epitope II of the RSV fusion (F) protein, blocking viral entry into host cells. The antibody features Fc segment engineering to extend its serum half-life, enabling season-long protection with a single intramuscular injection. Simcere Pharmaceutical Group holds exclusive commercialization rights in Greater China. Yingmule was approved by China's National Medical Products Administration (NMPA) on September 3, 2026.

Brand names: YingMuLe
Other names: culevibart injection

Targets

RSV F (Respiratory syncytial virus fusion protein)

Beyond the preview

Go deeper on culevibart.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on culevibart.